EFFECT OF SUGAMMADEX AND NEOSTIGMINE ON BLOOD GLUCOSE LEVEL:A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Objectives: Sugammadex is offered as a recent alternative to cholinesterase inhibitors in reversing neuromuscular block. Sugammadex is a cyclodextrin molecule that is consisted of bounded sugar molecules. Given its chemical structure, sugammadex may increase blood glucose levels. We aimed to investigate the effect of sugammadex on blood glucose and compare sugammadex to the conventional reverse agent Neostigmine. Methods: Sixty patients undergoing medium-term abdominal surgery under general anesthesia were included in this study. The patients were randomly divided into two groups: Group N (n = 30) and Group S (n = 30). The dose of 50 μg/kg Neostigmine and 20 μg/kg atropine was administered for the patients in Group N and 2 mg/kg sugammadex was administered for the patients in Group S. Blood glucose levels were measured at 15 minutes before (T1) and at 30th minute of surgery (T2). Blood glucose levels were recorded 30 minutes (T3), 2 hours (T4) and 4 hours (T5) after administration of the reversing agent. Results: Blood glucose levels that were measured at T3, T4 and T5 were significantly higher in Group S compared to Group N (p<0.05). We consider that sugammadex contains glucose molecules and does not bind to plasma proteins, may cause an increase in blood glucose level and this increase may be associated with chemical structure of sugammadex rather than surgical stress of patients.
Warner DS, Gionet TX, Todd MM, Mc Allister AM. Insulin induced normoglycemia improves ischemic outcome in hyperglycemic rats. Stroke. 1992; 23 (12): 1775-81.
Schricker T, Lattermann R, Schreiber M, Geisser W, Georgieff M, Radermacher P. The hyperglycaemic response to surgery: pathophysiology, clinical implications and modification by the anaesthetic technique. Clinica Intensive Care. 1998; 9 (3): 118-28.
Kim YB, Sung TY, Yang HS. Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents. Korean J Anesthesiol. 2017; 70(5): 500-10.
Paech MJ, Kaye R, Baber C, Nathan EA. Recovery characteristics of patients receiving either sugammadex or neostigmine and glycopyrrolate for reversal of neuromuscular block: a randomised controlled trial. Anaesthesia. 2017 Dec 7. [Epub ahead of print]
Tajaate N, Schreiber JU, Fuchs-Buder T, Jelting Y, Kranke P. Neostigmine-based reversal of intermediate acting neuromuscular blocking agents to prevent postoperative residual paralysis: A systematic review. Eur J Anaesthesiol 2017 Nov 20. [Epub ahead of print]
Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent toreverse the action of rocuronium bromide. Anesthesiology. 2005; 103(4): 695-703.
Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006; 104(4): 667-74.
de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth. 2006; 96(2): 201-6.
Caldwell JE, Miller RD. Clinical implications of sugammadex. Anaesthesia. 2009; 64 (Suppl 1): 66-72.
Harada A. 2001. Cyclodextrin-based molecular machines. Acc Chem Res. 2001; 34(6): 456-64.
Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017; 8: CD012763.
Allison SP, Tomlin PJ, Chamberlain MJ. Some effects of anaesthesia and surgery on carbohydrate and fat metabolism. Br J Anaesth. 1998; 81(2): 273-7.
Carson J, Scholz PM, Chen AY, Peterson FD, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol. 2002; 40(3): 418-23.
Crini G, Morcellet M. Synthesis and applications of adsorbents containing cyclodextrins. J Sep Sci. 2002; 25(13):789–813.
Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006; 96(1): 36-43.
Summary of product characteristics (Sugammadex) https://ec.europa.eu/health/documents/communityregister/2016/20160226134295/anx_134295_en.pdf
Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007; 106(2): 283-8.
Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Reversal of rocuronium- induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlledtrial. Eur J Anaesthesiol. 2010; 27(10): 87481.
Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of proufond rocuronium induced blockade with sugammadex a randomized comparison with neostigmine. Anesthesiology. 2008; 109(5): 816-24.
Kiraz HA, Turgut HC, Kartal S, Comu FM, Kip G, Alkan M, et al. Effect of low and high dose sugammadex on erythrocyte deformability in streptozotocin-induced diabetic rats. Gazi Med J 2015; 26(3): 107-9.
Ignacio AB, Felix LS, Luciano AC, Diego DZ, Andrees GL, Enrique FJ. Neuromuscular block reversal with sugammadex in type 2 diabetic patients. Perioperative Care and Operating Room Management 2015; (1)1: 13-18.
- There are currently no refbacks.
Copyright (c) 2018 Mehmet Akif Yazar
This work is licensed under a Creative Commons Attribution 4.0 International License.